Drug sensitivity profiling highlighted JAK inhibitors as effective targeted therapy candidates, in line with the central role of IL-2 signaling in NK cells and the JAK-STAT pathway alterations observed in ANKL and NKTCL. This evidence concerns the gene IL2 and extranodal nasal NK/T cell lymphoma.